Breast Tangents: Unexpected Skin Reaction Mid-Course
A 54-year-old woman is receiving whole-breast radiotherapy after lumpectomy, 42.5 Gy in 16 fractions with a 10 Gy boost to the tumor bed. At fraction 11 she presents with moist desquamation in the inframammary fold, measuring 4 × 3 cm, with moderate pain (5/10). Her treatment plan uses opposed tangential fields with a 1 cm bolus applied only for the first 5 fractions. She has a BMI of 34 and a large breast volume. The inframammary fold lies within the high-dose region, and the plan's skin dose estimate was not explicitly modeled. She is due for the boost after fraction 16. She asks whether she can 'just skip the rest' because the skin is so sore.
1. How should the therapist assess and grade this reaction, and what immediate management is appropriate?
Read the worked answer
The therapist should inspect and document the reaction using a validated scale (CTCAE or RTOG). Moist desquamation confined to a fold, with moderate pain, is typically grade 2 (RTOG) or grade 2–3 (CTCAE) and warrants physician review. Immediate management includes: confirm the area is kept clean and dry, use prescribed non-metallic topical agents (e.g., silver sulfadiazine or hydrocortisone per institutional protocol), avoid tight clothing and friction, and consider a skin-care referral. The therapist should verify the bolus was removed after fraction 5 and that no bolus remains. Because the fold is in the high-dose region in a large-breasted patient, the therapist should flag the case to the physicist/oncologist to review the plan's skin dose and consider a small field adjustment or a break if grade 3 worsens. The patient should be reassured that the reaction is expected and manageable, and that skipping treatment would compromise local control.
2. What is the clinical and dosimetric reasoning for not simply omitting the remaining fractions or the boost?
Read the worked answer
Omitting the boost or remaining fractions reduces the biologically effective dose to the tumor bed, which is the highest-risk region for local recurrence after lumpectomy. The 42.5 Gy/16 schedule is already a hypofractionated regimen with an α/β-adjusted dose; dropping the 10 Gy boost lowers the tumor bed dose by roughly 20–25% and removes the deliberate escalation targeted at the resection cavity. The skin reaction, while uncomfortable, is self-limited and typically peaks 1–2 weeks after treatment; it does not justify a survival or recurrence risk. The correct approach is to manage the skin, consider a short treatment break only if grade 3–4 toxicity develops (and even then, coordinate with the oncologist because breaks can reduce efficacy), and continue. The therapist should also check whether the boost can be delivered with a smaller field or electrons to spare the fold, and document the discussion.